Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group
Open accessAbstract
BACKGROUND: The addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP‐PE) to chemotherapy has been shown to improve overall survival in patients with nonmetastatic osteosarcoma (OS). The authors report the results of addition of liposomal MTP‐PE to chemotherapy for patients with metastatic OS. METHODS: Intergroup‐0133 was a prospective randomized phase 3 trial for the treatment of newly diagnosed patients with OS. The authors compared 3‐drug chemotherapy with cisplatin, doxorubicin, and high‐dose methotrexate (Regimen A) to the same 3 drugs with the addition of ifosfamide (Regimen B). The addition of liposomal MTP‐PE to chemotherapy was evaluated. RESULTS: Five‐year event‐free survival (EFS) for patients who received liposomal MTP‐PE (n = 46) was 42% versus 26% for those who did not (n = 45) (relative risk for liposomal MTP‐PE, 0.72; P = .23; 95% confidence interval [CI], 0.42‐1.2). The 5‐year overall survival for patients who received MTP‐PE versus no MTP‐PE was 53% and 40%, respectively (relative risk for liposomal MTP‐PE, 0.72; P = 0.27; 95% CI, 0.40‐1.3). The comparison of Regimen A with Regimen B did not suggest a difference for EFS (35% vs 34%, respectively; relative risk for Regimen B, 1.07; P = .79; 95% CI, 0.62‐1.8) or overall survival (52% vs 43%, respectively; relative risk for Regimen B, 1.1, P = .75; 95% CI, 0.61‐2.0). CONCLUSIONS: When the metastatic cohort was considered in isolation, the addition of liposomal MTP‐PE to chemotherapy did not achieve a statistically significant improvement in outcome. However, the pattern of outcome is similar to the pattern in nonmetastatic patients. Cancer 2009. © 2009 American Cancer Society.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
L-MTP-PE in patients with metastatic osteosarcoma was not found to improve event-free or overall survival.
“The use of L-MTP-PE in patients with metastatic osteosarcoma was not found to improve event-free or overall survival and should not be used outside of clinical trials 130 .”
From Osteosarcoma (2022) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875 · see citing works
The Statistical Analysis of Failure Time Data
Young, W. R. (1981) · Journal of Quality Technology · doi:10.1080/00224065.1981.11978770 · Cited by 1,708 · see citing works
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934 · see citing works
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · see citing works
Self-citationMeyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717 · see citing works
Self-citationPrognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy
Bacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P. (2006) · Cancer · doi:10.1002/cncr.21724 · Cited by 567 · see citing works
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Applewhite, A., Sun, M., & LaQuaglia, M. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 389 · see citing works
Self-citationMeyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294 · see citing works
Self-citationMetastatic osteosarcoma at diagnosis
Mialou, V., Philip, T. O., Kalifa, C., Pérol, D., Gentet, J., Marec‐Bérard, P., Pacquement, H., Chastagner, P. B., Defaschelles, A.-S., & Hartmann, O. (2005) · Cancer · doi:10.1002/cncr.21263 · Cited by 283 · see citing works
MacEwen, E. G., Kurzman, I. D., ROSENTHAL, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.12.935 · Cited by 227 · see citing works
Bacci, G., Briccoli, A., Rocca, M., Ferrari, S., Donati, D. M., Longhi, A., Bertoni, F., Bacchini, P., Giacomini, S., Forni, C., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg286 · Cited by 187 · see citing works
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII
Smeland, S., Müller, C., Alvegård, T. A., Wiklund, T. A., Wiebe, T., Björk, O., Stenwig, A. E., Willén, H., Holmström, T., Follerås, G., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00747-5 · Cited by 165 · see citing works
Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157 · see citing works
Self-citationBacci, G., Longhi, A., Forni, C., Setola, E., & Ferrari, E. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00546-x · Cited by 155 · see citing works
Nardin, A., Lefebvre, M., Labroquère, K., Faure, O., & Abastado, J. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056473 · Cited by 133 · see citing works
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma
Kleinerman, E. S., Gano, J. B., Johnston, D. A., Benjamin, R. S., & Jaffe, N. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00001 · Cited by 116 · see citing works
Self-citationDaw, N. C., Billups, C. A., Galindo, C. R., McCarville, M. B., Rao, B. N., Cain, A. M., Jenkins, J. J., Neel, M. D., & Meyer, W. H. (2005) · Cancer · doi:10.1002/cncr.21626 · Cited by 112 · see citing works
Liposome-Encapsulated MTP-PE: A Novel Biologic Agent for Cancer Therapy
Asano, T., & Kleinerman, E. S. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199311000-00006 · Cited by 60 · see citing works
Self-citationCombination Therapy with Ifosfamide and Liposome-Encapsulated Muramyl Tripeptide
Kleinerman, E. S., Meyers, P. A., Raymond, A. K., Gano, J. B., Jia, S.-F., & Jaffe, N. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199504000-00007 · Cited by 57 · see citing works
Self-citationBiologic Therapy for Osteosarcoma Using Liposome-Encapsulated Muramyl Tripeptide
Kleinerman, E. S. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30079-0 · Cited by 47 · see citing works
Self-citationKurzman, I. D., Shi, F., Vail, D. M., & MacEwen, E. G. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.121 · Cited by 46 · see citing works
Seibel, N. L., Krailo, M., Chen, Z., Healey, J. H., Breitfeld, P. P., Drachtman, R. A., Greffe, B. S., Nachman, J. B., Nadel, H. R., Sato, J. K., et al. (2007) · Cancer · doi:10.1002/cncr.22553 · Cited by 44 · see citing works
Self-citationNovel therapeutic approaches in pediatric and young adult sarcomas
Anderson, P. M., & Pearson, M. G. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0038-0 · Cited by 43 · see citing works
MacEwen, E. G., Kurzman, I. D., Helfand, S. C., Vail, D. M., London, C. A., Kisseberth, W. C., ROSENTHAL, R. C., Fox, L. E., Keller, E. T., Obradovich, J. E., et al. (1994) · Journal of drug targeting · doi:10.3109/10611869408996814 · Cited by 40 · see citing works
Anderson, P. M. (2006) · Future Oncology · doi:10.2217/14796694.2.3.333 · Cited by 40 · see citing works
Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific
Gorlick, R. G., & Meyers, P. A. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200311000-00003 · Cited by 33 · see citing works
Self-citationKleinerman, E. S., Maeda, M., & Jaffe, N. (1993) · Cancer treatment and research · doi:10.1007/978-1-4615-3518-8_14 · Cited by 26 · see citing works
Self-citationMcTiernan, A., Meyer, T., Michelagnoli, M. P., Lewis, I. J., & Whelan, J. S. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20562 · Cited by 11 · see citing works
del Prever, A. B., Fagioli, F., Berta, M., Bertoni, F., Ferrari, S., & Mercuri, M. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000150739.73067.f3 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · see citing works
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · see citing works
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876 · see citing works
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. B., Lewis, V. O., & Gorlick, R. G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 688 · see citing works
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551 · see citing works
Self-citationNanomedicine review: clinical developments in liposomal applications
Beltran-Gracia, E., López-Camacho, A., Higuera‐Ciapara, I., Velázquez-Fernández, J. B., & Vallejo‐Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 515 · see citing works
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513 · see citing works
Lindsey, B. A., Markel, J., & Kleinerman, E. S. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 490 · see citing works
Self-citationReview of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 397 · see citing works
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359 · see citing works
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 300 · see citing works
New targets and approaches in osteosarcoma
Gill, J. B., Ahluwalia, M., Geller, D., & Gorlick, R. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 274 · see citing works
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 271 · see citing works
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy
Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G. E., Santucci, A., Vermi, W., & Giurisato, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155207 · Cited by 280 · see citing works
Osteosarcoma: A comprehensive review of management and treatment strategies
Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253 · see citing works
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226 · see citing works
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 225 · see citing works
An update on chemotherapy for osteosarcoma
Ferrari, S. M., & Serra, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1102226 · Cited by 212 · see citing works
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
PosthumaDeBoer, J., Witlox, A. M. A., Kaspers, G. J. L., & van Royen, B. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9384-x · Cited by 192 · see citing works
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma
Dumars, C., Ngyuen, J.-M., Gaultier, A., Lanel, R., Corradini, N., Gouin, F., Heymann, D., & Heymann, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13055 · Cited by 174 · see citing works
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Roth, M. E., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R. S., Geller, D., Gill, J. B., & Gorlick, R. G. (2013) · Cancer · doi:10.1002/cncr.28461 · Cited by 168 · see citing works
Epidemiology and therapies for metastatic sarcoma
Reed, D. R., Amankwah, & Conley, A. P. (2013) · Clinical Epidemiology · doi:10.2147/clep.s28390 · Cited by 154 · see citing works
Advances in the management of osteosarcoma
Bielack, S., Hecker‐Nolting, S., Blattmann, C., & Kager, L. (2016) · F1000Research · doi:10.12688/f1000research.9465.1 · Cited by 152 · see citing works
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 143 · see citing works
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124 · see citing works
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Meyers, P. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.69 · Cited by 130 · see citing works
Self-citationPresent Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
Shaikh, A. B., Li, F., Li, M., He, B., He, X., Chen, G., Guo, B., Li, D., Jiang, F., Dang, L., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040506 · Cited by 124 · see citing works
Review of mifamurtide in the treatment of patients with osteosarcoma
Kager, L., Pötschger, U., & Bielack (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5688 · Cited by 124 · see citing works
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 123 · see citing works
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 118 · see citing works
The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118 · see citing works
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 103 · see citing works
Pahl, J. H., Kwappenberg, K., Varypataki, E., Santos, S., Kuijjer, M., Mohamed, S., Wijnen, J., van Tol, M. V., Cleton-Jansen, A., Egeler, R., et al. (2014) · Journal of experimental & clinical cancer research : CR · doi:10.1186/1756-9966-33-27 · Cited by 94 · see citing works
Emerging drugs for high-grade osteosarcoma
Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P., & Serra, M. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505603 · Cited by 99 · see citing works
Advances in emerging drugs for osteosarcoma
Hattinger, C. M., Fanelli, M., Tavanti, E., Vella, S., Ferrari, S. M., Picci, P., & Serra, M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051965 · Cited by 94 · see citing works
Zhang, B., Zhang, Y., Li, J., Lu, X., Lu, X., & Zhang, Y. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-1576-0 · Cited by 95 · see citing works
Chen, L., Oke, T. F., Siegel, N. M., Cojocaru, G., Tam, A. J., Blosser, R. L., Swailes, J., Ligon, J. A., Lebid, A., Morris, C. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3416 · Cited by 92 · see citing works
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90 · see citing works
Green, D. M., Kun, L. E., Matthay, K. K., Meadows, A. T., Meyer, W. H., Meyers, P. A., Spunt, S. L., Robison, L. L., & Hudson, M. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24487 · Cited by 88 · see citing works
Self-citationRen, H., Sun, L., Li, H., & Ye, Z. (2015) · BioMed Research International · doi:10.1155/2015/160835 · Cited by 88 · see citing works
Ohba, T., Cole, H., Cates, J., Slosky, D., Haro, H., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2182 · Cited by 84 · see citing works
Origin and Therapies of Osteosarcoma
Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 83 · see citing works
Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
van Oosterwijk, J. G., Anninga, J., Gelderblom, H. A. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.012 · Cited by 81 · see citing works
Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 82 · see citing works
Meyers, P. A., & Chou, A. J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_17 · Cited by 79 · see citing works
Self-citationInnate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 76 · see citing works
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 75 · see citing works
Self-citationPallares, R. M., Barmin, R. A., Wang, A., Kiessling, F. M., & Lammers, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113991 · Cited by 77 · see citing works
Goldsby, R. E., Fan, T. M., Villaluna, D., Wagner, L. M., Isakoff, M. S., Meyer, J. S., Randall, R. L., Lee, S. C. L., Kim, G., Bernstein, M. L., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.018 · Cited by 72 · see citing works
Self-citationPrognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis
Chen, J., Sun, M., Hua, Y., & Cai, Z. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1644-0 · Cited by 69 · see citing works
Managing sarcoma: where have we come from and where are we going?
Bleloch, J., Ballim, R. D., Kimani, S., Parkes, J., Panieri, E., Willmer, T., & Prince, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728927 · Cited by 68 · see citing works
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68 · see citing works
The Current and Future Therapies for Human Osteosarcoma
Lamplot, J. D., Denduluri, S. K., Qin, J., Li, R., Liu, X., Zhang, H., Chen, X., Wang, N., Pratt, A., Shui, W., et al. (2013) · Current Cancer Therapy Reviews · doi:10.2174/1573394711309010006 · Cited by 67 · see citing works
Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma
Fu, Y., Lan, T., Cai, H., Lu, A., & Yu, W. (2018) · Medicine · doi:10.1097/md.0000000000010741 · Cited by 68 · see citing works
Chen, B., Zeng, Y., Liu, B., Lu, G., Xiang, Z., Chen, J., Yan, Y., Zuo, Z., Lin, Y., & Ma, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672024 · Cited by 66 · see citing works
Immunotherapy of Childhood Sarcomas
Roberts, S. S., Chou, A. J., & Cheung, N. V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00181 · Cited by 66 · see citing works
Self-citationTherapeutic Targets for Bone and Soft-Tissue Sarcomas
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010170 · Cited by 65 · see citing works
Surgical treatment of pulmonary metastases in pediatric solid tumors
Heaton, T. E., & Davidoff, A. M. (2016) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2016.09.001 · Cited by 63 · see citing works
Drugs in early clinical development for the treatment of osteosarcoma
Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 62 · see citing works
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease
Harrison, D. J., & Schwartz, C. L. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0464-2 · Cited by 62 · see citing works
Current Treatment Considerations for Osteosarcoma Metastatic at Presentation
Tsukamoto, S., Errani, C., Angelini, A., & Mavrogenis, A. F. (2020) · Orthopedics · doi:10.3928/01477447-20200721-05 · Cited by 59 · see citing works
Sarcoma Immunotherapy: Past Approaches and Future Directions
D’Angelo, S. P., Tap, W. D., Schwartz, G. K., & Carvajal, R. D. (2014) · Sarcoma · doi:10.1155/2014/391967 · Cited by 61 · see citing works
Anderson, M. E., Randall, R. L., Springfield, D. S., & Gebhardt, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00092-8 · Cited by 59 · see citing works
Meyers, P. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_11 · Cited by 61 · see citing works
Self-citationPathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
Aleynick, M., Svensson‐Arvelund, J., Flowers, C. R., Marabelle, A., & Brody, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1800 · Cited by 59 · see citing works
Roth, M. E., Barris, D. M., Piperdi, S., Kuo, V. F.-H., Everts, S., Geller, D., Houghton, P. J., Kolb, E. A., Hawthorne, T. R., Gill, J. B., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25688 · Cited by 58 · see citing works
Zabielska-Koczywąs, K. A., & Lechowski, R. (2017) · Molecules · doi:10.3390/molecules22122167 · Cited by 58 · see citing works
Bone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 57 · see citing works
Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma
Hao, H., Chen, L., Huang, D., Ge, J., Qiu, Y., & Hao, L. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12536 · Cited by 57 · see citing works
Immunotherapeutic Approaches to Sarcoma
Burgess, M. A., & Tawbi, H. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0345-5 · Cited by 55 · see citing works
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 55 · see citing works
Li, X., Chen, Y., Liu, X., Zhang, J. C., Xu, H., Teng, G., & Yu, D. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.01.006 · Cited by 54 · see citing works
Current questions in bone sarcomas
Strauss, S. J., & Whelan, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000456 · Cited by 49 · see citing works
Brard, C., Piperno-Neumann, S., Delaye, J., Brugières, L., Hampson, L. V., Teuff, G. L., Deley, M. L., & Gaspar, N. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025877 · Cited by 48 · see citing works
Meazza, C., Cefalo, G., Massimino, M., Daolio, P. A., Pastorino, U., Scanagatta, P., Morosi, C., Podda, M. G., Ferrari, A., Terenziani, M., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-1052-9 · Cited by 47 · see citing works
Strategies and developments of immunotherapies in osteosarcoma
WAN, J., Zhang, X., Liu, T., & Zhang, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3962 · Cited by 46 · see citing works
Molecular pathogenesis and therapeutic strategies of human osteosarcoma
Denduluri, S. K., Wang, Z., Yan, Z., Wang, J., Wei, Q., Mohammed, M. K., Haydon, R. C., Luu, H. H., & He, T. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150075 · Cited by 45 · see citing works
Local Control of Soft Tissue and Bone Sarcomas
Crompton, J. G., Ogura, K., Bernthal, N. M., Kawai, A., & Eilber, F. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2717 · Cited by 45 · see citing works
Rajani, R., & Gibbs, C. P. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2011.07.015 · Cited by 42 · see citing works
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 42 · see citing works
Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis
Li, S., Yang, Q., Wang, H., Wang, Z., Zuo, D., Cai, Z., & Hua, Y. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1066 · Cited by 40 · see citing works
Translation of peptidoglycan metabolites into immunotherapeutics
Griffin, M. E., Hespen, C. W., Wang, Y., & Hang, H. C. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1095 · Cited by 40 · see citing works
Jimmy, R., Stern, C., Lisy, K., & White, S. (2017) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-003105 · Cited by 39 · see citing works
Kany, S., Woschek, M., Kneip, N., Sturm, R., Kalbitz, M., Hanschen, M., & Relja, B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4288 · Cited by 39 · see citing works
LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR‐361‐5p and FoxM1
Shen, B., Zhou, N., Hu, T., Zhao, W., Wu, D., & Wang, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28026 · Cited by 38 · see citing works
Immune-Based Therapies for Sarcoma
Pollack, S. M., Loggers, E. T., Rodler, E. T., Yee, C., & Jones, R. L. (2011) · Sarcoma · doi:10.1155/2011/438940 · Cited by 37 · see citing works
Rodrigues, J., Sarmento, B. F. C. C., & Pereira, C. L. (2022) · In vitro models · doi:10.1007/s44164-022-00008-x · Cited by 39 · see citing works
Biteau, K., Guiho, R., Chatelais, M., Taurelle, J., Chesneau, J., Corradini, N., Heymann, D., & Rédiní, F. (2016) · PubMed Central · Cited by 36 · see citing works
Venkatakrishnan, K., Liu, Y., Noe, D. A., Mertz, J., Bargfrede, M., Marbury, T. C., Farbakhsh, K., Oliva, C., & Milton, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12260 · Cited by 35 · see citing works
Heaton, T. E., Hammond, W. J., Farber, B. A., Pallos, V., Meyers, P. A., Chou, A. J., Price, A. P., & LaQuaglia, M. P. (2016) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2016.10.034 · Cited by 35 · see citing works
Self-citationTargeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 34 · see citing works
Nakata, E., Fujiwara, T., Kunisada, T., Ito, T., Takihira, S., & Ozaki, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab005 · Cited by 35 · see citing works
Zhra, M., Akhund, S. A., & Mohammad, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18040520 · Cited by 36 · see citing works
Hung, G., Yen, H., Yen, C., Chen, W., Chen, P. C.-H., Wu, H.-T. H., Chiou, H., Chang, W., & Hsu, H.-E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4154-z · Cited by 34 · see citing works
van Maldegem, A. M., Bhosale, A., Gelderblom, H. A. J., Hogendoorn, P. C. W., & Hassan, A. B. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-5 · Cited by 33 · see citing works
Value of ablation therapy in the treatment of lung metastases
Qi, H., & Fan, W. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12567 · Cited by 32 · see citing works
The Use of Phospholipids to Make Pharmaceutical Form Line Extensions
van Hoogevest, P., Tiemessen, H. L. G. M., Metselaar, J. M., Drescher, S., & Fahr, A. (2021) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.202000297 · Cited by 33 · see citing works
Malignant and Metastatic Tumors of the Hand
Puhaindran, M. E., & Athanasian, E. A. (2010) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2010.08.014 · Cited by 32 · see citing works
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
Fan, X.-L., Cai, G.-P., Zhu, L.-L., & Ding, G. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s91217 · Cited by 32 · see citing works
- Authors
- Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., Womer, R. B., Meyers, P. A., & on behalf of the Children's Oncology Group
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Children's Oncology Group (US)
- Mayo Clinic (US)
- University of Washington (US)
- Johns Hopkins All Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Meyers, Paul A.
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-11-03
- Volume
- 115
- Issue
- 22
- Pages
- 5339-5348
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2783515
- OpenAlex
- W2058138047
- Cited by
- 245
- References
- 29
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 17 · 2021: 19 · 2020: 29 · 2019: 15 · 2018: 14 · 2017: 22 · 2016: 20 · 2015: 19 · 2014: 16 · 2013: 19 · 2012: 7
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U10 CA-98413, U10-CA98543, U10CA098413, P01CA106450, U10CA098543)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- muramyl tripeptide phosphatidylethanolamine, metastatic osteosarcoma, ifosfamide, cisplatin, doxorubicin, high-dose methotrexate, event-free survival, overall survival
- MeSH terms
- Acetylmuramyl-Alanyl-Isoglutamine, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Drug Administration Schedule, Female, Humans, Immunologic Factors, Infant, Infant, Newborn, Male, Neoplasm Metastasis, Phosphatidylethanolamines, Osteosarcoma, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
